Literature DB >> 11124676

Oral erythromycin treatment for childhood blepharokeratitis.

D M Meisler1, M B Raizman, E I Traboulsi.   

Abstract

Blepharokeratitis is a chronic external ocular and adnexal inflammatory condition marked by erythematous and edematous lid margins, lid margin crusting and scaling, meibomian gland inflammation and inspissation, and conjunctival hyperemia. The associated keratitis usually involves the inferior cornea and is characterized by punctate epithelial keratopathy and marginal stromal infiltrates. The inflammation sometimes leads to corneal thinning, scarring, and vascularization. The standard therapy for adult blepharokeratitis includes lid hygiene, topical cortico-steroid preparations, and topical antibiotics. Oral tetracycline and its analogues, doxycycline and minocycline, are used in adults to treat associated meibomian gland dysfunction. Whereas blepharitis is common in children, blepharokeratitis is rare and is often associated with severe ocular and psychosocial morbidity. Treatment of youths may be problematic because of poor compliance with lid hygiene and therapy that includes drops and ointment.(1) Furthermore, the use of tetracycline and its analogues is contraindicated in children aged less than 8 years because it may cause dental enamel abnormalities. Isolated case reports have suggested that erythromycin may be a reasonable alternative to tetracycline in childhood blepharokeratitis.(2,3) We report on the successful treatment of this condition with oral erythromycin in 5 children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124676     DOI: 10.1067/mpa.2000.110339

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  9 in total

Review 1.  The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee.

Authors:  Penny A Asbell; Fiona J Stapleton; Kerstin Wickström; Esen K Akpek; Pasquale Aragona; Reza Dana; Michael A Lemp; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 2.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

3.  Blepharokeratoconjunctivitis in children: diagnosis and treatment.

Authors:  M Viswalingam; S Rauz; N Morlet; J K G Dart
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

Review 4.  Topical treatments for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Catey Bunce; Melanie Hingorani; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2017-02-07

5.  Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.

Authors:  Surya P Ayalasomayajula; Uday B Kompella
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

6.  Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome.

Authors:  A Rodríguez-García; S González-Godínez; S López-Rubio
Journal:  Eye (Lond)       Date:  2015-12-04       Impact factor: 3.775

7.  Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children.

Authors:  Daniel S Choi; Ali Djalilian
Journal:  J AAPOS       Date:  2013-01-27       Impact factor: 1.220

Review 8.  Systemic treatment for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Marina Banteka; Catey Bunce; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2016-05-30

9.  Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis.

Authors:  Serge Doan; Eric Gabison; Frédéric Chiambaretta; Melissa Touati; Isabelle Cochereau
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.